Z.I. de Brais - 1 rue Graham Bell
44600 Saint Nazaire
Tél. : + 33 (0)2 51 10 01 00
Dear valued client,
We are pleased to inform you that Charles River Laboratories International, Inc. (CRL) and Citoxlab have entered today into exclusive discussions pursuant to an exclusivity agreement for the intended acquisition by Charles River of CTL International, the holding company of Citoxlab. The closing should occur Q2 after customary regulatory procedures and subject to appropriate labor consultations.
Citoxlab has been a fast growing early-stage Contract Research Organization (CRO) over the last few years and recently became a top CRO in the non-clinical research market. With 6 sites covering Europe (Evreux, Saint-Nazaire in France, Veszprem, Szeged and Budapest in Hungary and Copenhagen in Denmark) and 3 sites in North America (Laval and Boisbriand in Canada; Kansas-City in USA), the company today employs more than 1500 staff and generated 155 million Euros of revenues in 2018.
This success story was only possible thanks to your continuous support. My teams and I are sincerely very grateful to you for this.
I believe that Charles River is a wonderful home for Citoxlab and that becoming a member of the Charles River family, the worldwide leader of the CRO industry, would be both an achievement and a recognition for our company and for everyone who works in it. After many years of strong growth, I am happy and excited that such a new era opens for Citoxlab.
We know that you value not only the quality of our work, but also the stability of the organizations you work with. We are pleased to inform you that Charles River agrees that Citoxlab would be a strategic acquisition for them and that they greatly value what we would be bringing to the new organization. Citoxlab adds great scientific expertise, complementary capabilities, talented people, and access to growing end markets for Charles River, and the Citoxlab sites enhance Charles River’s global footprint.
In a time when the number of new drug candidates are increasing and when projects are more and more complex, we are convinced that the combination of the teams, the sharing of our respective best practices and the synergies between the services offered by Charles River and by Citoxlab would represent a real opportunity for you, our clients.
Our goal is to join our resources and continue our best efforts to meet your needs with the quality, flexibility and agility we know that you need and expect, and we will always be committed and enthusiastic to contribute to the development of your innovative and safe new products.
It is important for you to understand that until the deal is finalized, it is business as usual for us, and you should continue to work with your usual Citoxlab contacts.
If you have any questions, please contact for Atlanbio site: “Dr Philippe Couerbe – General Manager - firstname.lastname@example.org – +33 6 29 58 98 45 or, Dr Mark Warren – Senior Director of Bioanalytical Services - email@example.com - + 33 6 03 75 90 85.”
Jean-François Le Bigot, Ph.D., President and Chief Executive Officer
An offer that makes the difference.
Atlanbio provides you with a large Mass Spectrometry instrumental platform (GC/MS and LC/MS). LC-MS/MS and LC-MS3 techniques are routinely used for the analysis of small molecules, peptides and proteins.
An offer that makes the difference.
Atlanbio provides you with a large variety of Immunochemistry techniques: micro plate-based assays (EIA, ECLIA), radioactive assays (RIA) and cell-biology techniques including cell-based assays. Immunoassays and full Immunogenicity testing package are available.
See our new company's movie.
Atlanbio holds new spacious premises well-designed and fully secured, since December 2010. These premises are a major contribution point to support the atlanbio GLP / GCP environment.